Tradjenta (linagliptin) tablets for type 2 diabetes approved by the FDA

This approval represents another treatment option for millions of Americans with type 2 diabetes. And ‘effective when used alone or when added to existing treatment regimens.Tradjenta tablets can be taken with or without food. Increase incretin levels, then the increase in insulin levels after meals and throughout the day.

According to the FDA, the patient information leaflet apprved FDA, claiming the use of drugs and risks will be included when the drug is dispensed.

When used alone , Tradjenta demonstrated a significant reduction in A1C to 0.7 percent. When taken with metformin, sulfonylurea and metformin plus sulphonylurea; tradjenta caused reduced HbA1c by 0.6 percent, 0.5 percent and 0.6 percent respectively

Many people with type 2 diabetes are not able to control their blood sugar with diet and exercise and may also require one or more drugs. TRADJENTA The FDA approval is exciting because there is only one dose to remember for all patients, regardless of renal impairment or hepatic impairment. With TRADJENTA, doctors will have another option for the management of type 2 diabetes, a potentially devastating.

Tradjenta has also been shown that these benefits:
Alone or in combination with metformin, a sulphonylurea or pioglitazone – a significant reduction in fasting plasma glucose compared to placebo. GIF is used to measure glucose levels after long periods without eating, for example when the patient wakes up in the morning.

Alone or in combination with metformin – a significant reduction in two-hour PPG . PPG is used to measure patient’s glucose levels after eating, usually two hours after eating. Mary Parks, MD, Director of the Division of Metabolism and Endocrinology Products at FDA Center for Drug Evaluation and Research, said:

The FDA has approved Tradjenta tablets to control blood sugar in adults with type two – for use with diet and exercise, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly announced today. Tradjenta can be used alone or in combination with metformin, a sulphonylurea or pioglitazone.

Tradjenta is not indicated for people with diabetic ketoacidosis or those with type 1 diabetes. The drug has not been tested in combination with insulin.

The FDA approved Tradjenta 5 mg once a day after the evaluation of a clinical trial program with about 4000 adult patients with type 2 diabetes. Placebo-controlled studies that evaluated Tradjenta himself and with other drugs for type 2 diabetes such as metformin, a sulfonylurea or pioglitazone, were included in the program.

Linagliptin has been shown to reduce hemoglobin A1c levels up to 0.7 percent compared to placebo.

A1C provides an indication of how the diabetic patient was able to control blood sugar levels over the past two months.

This entry was posted in clinical. Bookmark the permalink.

Comments are closed.